Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation versus Sitagliptin in Subjects with Type 2 Diabetes Mellitus. A 52 week Randomised, Open-label, Active-controlled Trial with a 52-week Extension Phase

Next Previous
Trial Profile

Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation versus Sitagliptin in Subjects with Type 2 Diabetes Mellitus. A 52 week Randomised, Open-label, Active-controlled Trial with a 52-week Extension Phase

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Semaglutide (Primary) ; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms PIONEER 7
  • Sponsors Novo Nordisk

Most Recent Events

  • 23 Sep 2022 Results of an exploratory analysis assessing time spent by patients with HbA1c <7.0% (53 mmol/mol), and likelihood of maintaining this glycaemic control using data from four clinical studies: PIONEER-2, PIONEER-3, PIONEER-4 and PIONEER-7 presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
  • 29 Jun 2021 Data from PIONEER 1-5, 7 AND 8 were used to assess BW loss, presented at the 81st Annual Scientific Sessions of the American Diabetes Association.
  • 29 Jun 2020 According to a Novo Nordisk media release, Rybelsus is administered orally once daily and is approved for use in three therapeutic dosages, 3 mg, 7 mg and 14 mg in Japan. The approved label reflects the Japanese studies.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top